Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple myeloma

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer

ASCO 2024: Highlights and analysis

ASCO 2024: Advances in NSCLC

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma

Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging safety profile and preliminary efficacy in RRMM